Skip to main content
PLOS One logoLink to PLOS One
. 2023 Apr 13;18(4):e0283589. doi: 10.1371/journal.pone.0283589

Mapping CircRNA–miRNA–mRNA regulatory axis identifies hsa_circ_0080942 and hsa_circ_0080135 as a potential theranostic agents for SARS-CoV-2 infection

Hassan Ayaz 1,#, Nouman Aslam 1,#, Faryal Mehwish Awan 1,*, Rabea Basri 1, Bisma Rauff 2, Badr Alzahrani 3, Muhammad Arif 1, Aqsa Ikram 4, Ayesha Obaid 1, Anam Naz 4, Sadiq Noor Khan 1, Burton B Yang 5,6,7, Azhar Nazir 1
Editor: Kanhaiya Singh8
PMCID: PMC10101458  PMID: 37053191

Abstract

Non-coding RNAs (ncRNAs) can control the flux of genetic information; affect RNA stability and play crucial roles in mediating epigenetic modifications. A number of studies have highlighted the potential roles of both virus-encoded and host-encoded ncRNAs in viral infections, transmission and therapeutics. However, the role of an emerging type of non-coding transcript, circular RNA (circRNA) in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has not been fully elucidated so far. Moreover, the potential pathogenic role of circRNA-miRNA-mRNA regulatory axis has not been fully explored as yet. The current study aimed to holistically map the regulatory networks driven by SARS-CoV-2 related circRNAs, miRNAs and mRNAs to uncover plausible interactions and interplay amongst them in order to explore possible therapeutic options in SARS-CoV-2 infection. Patient datasets were analyzed systematically in a unified approach to explore circRNA, miRNA, and mRNA expression profiles. CircRNA-miRNA-mRNA network was constructed based on cytokine storm related circRNAs forming a total of 165 circRNA-miRNA-mRNA pairs. This study implies the potential regulatory role of the obtained circRNA-miRNA-mRNA network and proposes that two differentially expressed circRNAs hsa_circ_0080942 and hsa_circ_0080135 might serve as a potential theranostic agents for SARS-CoV-2 infection. Collectively, the results shed light on the functional role of circRNAs as ceRNAs to sponge miRNA and regulate mRNA expression during SARS-CoV-2 infection.

Introduction

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), an enveloped RNA virus with a genome size of 29,903 bp, is a highly infectious and pathogenic coronavirus [1]. Initially, on December 31, 2019, China reported unusual viral pneumonia outbreak in the city of Wuhan. Since then, the virus SARS-CoV-2 that causes the COrona VIrus Disease 2019 (COVID-19) has evolved into a pandemic. Currently, >750 million people have been infected globally while >6.8 million people have lost their lives due to COVID-19 (World Health Organization, February 22, 2023). Once inside the host cell, SARS-CoV-2 triggers strong innate immune response with excessive production and infiltration of pro-inflammatory cytokines resulting in COVID-19 associated cytokine storm [2]. A cytokine storm is an umbrella term which describes a kind of hyper-inflammatory reaction that can result in life threatening systemic inflammation, immune dysregulation and multi-organ failure if left untreated [3]. These inflammatory mediators are being intricately controlled by regulatory machinery employed by the host cell [4]. Researchers initially focused upon studying disease pathogenesis and development of vaccines in response to COVID-19 pandemic. However, currently more focus has shifted towards elucidating the molecular mechanisms involved in various pathological responses exhibited during the course of infection. It is postulated that differentially expressed non-coding RNAs (ncRNAs) might be implicated in the regulation of the cellular processes which regulate the SARS-CoV-2 pathogenicity and cytokine-mediated immune responses [5]. Current study focuses on the premise that the variations in expression of these ncRNAs may possibly present a novel avenue to explore the pathogenesis of COVID-19.

Recent advances in high-throughput sequencing technologies and computational methods have discovered a substantial number of ncRNA ultimately providing new insights into their role in a range of human diseases [6, 7]. Various studies have shown that the ncRNAs, which include microRNAs (miRNAs), long non-coding RNAs (lncRNAs), and circular RNAs (circRNAs) play a crucial role in the progression of viral diseases [710]. miRNAs, one of the type of ncRNA are quite well studied and are known to play a pivotal role in the regulation of many genes, especially those at intersections of signaling pathways involved in development and growth control [11, 12]. Interestingly, viruses have been reported to interact with cellular miRNAs to manipulate both viral and cellular gene expression as well as to augment their replication potential [7, 13]. Moreover, miRNAs regulate viral persistence, host immune evasion and long-term survival in the host cell [14, 15]. Likewise, the expression of cellular lncRNAs may also be altered in response to viral replication inside the cell. It has been reported that many cellular lncRNAs are expressed in response to the antiviral pathways activated by viral infections [10, 16]. It is important to note that lncRNAs utilized by the viral machinery to enhance its replication could be those lncRNAs which are up-regulated in response to viral infections. Similarly, to counteract viral infection, the host cell has evolved to generate various cellular lncRNAs [10].

On the other hand, circRNAs, a novel class of ncRNAs have been reported to play crucial role in regulating viral infections and their dysregulation has been implicated in the pathogenesis of various diseases [17, 18]. While the biological functions of the majority of circRNAs are still not established, accumulating piece of evidence confirms that circRNAs perform many regulatory functions via translocating or sequestering proteins, exerting transcriptional and translational control as well as facilitating interactions between proteins [18]. circRNAs play multifunctional roles hence they are implicated in a range of biological and pathological processes that may affect the progression of several diseases including viral infections [19, 20]. Moreover, circRNAs modulate the innate immune responses during viral infections as well. Additionally, circRNAs have also been recommended as biomarkers for differentiating viral from non-viral infections [21, 22].

The circRNA–miRNA–mRNA regulatory axis has been shown to be of high importance in association with several human diseases including cancers, diabetes, Alzheimer’s disease, and cardiovascular diseases [2325]. These networks are involved in signaling pathways of different human diseases by regulating expression profiling of pathogenicity-related genes [24]. In essence, circRNAs regulates the expression of downstream target genes of miRNA, in turn miRNA can decrease the stability of the mRNA or in other words inhibit the translation of the mRNA by targeting its 3′-untranslated region (UTR), thus, negatively regulating the expression of the target genes [26]. Increasing evidence has suggested that this regulatory axis might also be involved in regulating crucial mechanisms in immune related response to SARS-CoV-2 [27].

There is an abundance of COVID-19 related transcriptomics studies and data, however, their use is limited by the confounding factors pertaining to each study. In the current study, we have analyzed different datasets in a unified approach which might help in understanding the molecular basis of COVID-19. Moreover, reverse engineering approach was utilized to derive regulatory interactions between circRNAs, miRNAs and mRNAs from gene expression data of SARS-CoV-2 patients. In order to gain better understanding of molecular and immuno-pathological basis, possible regulatory mechanisms of circRNA-miRNA-mRNA axis during SARS-CoV-2 infection were investigated. The circRNA–miRNA–mRNA regulatory network consisting of differentially expressed circRNAs and their downstream miRNAs and target mRNAs have been constructed for SARS CoV-2 related pathogenesis. The circRNAs that may play critical roles in regulating the cytokine storm during SARS-CoV-2 infection were identified. The results from this study revealed some candidate circRNAs that might function as potential theranostic agents in SARS-CoV-2 infection. Moreover, targeting the "cytokine storm" using circRNAs might be a feasible therapeutic approach to combat COVID-19 (Fig 1). Together, this research provides new insights into the triple regulatory network controlled by the circRNA–miRNA–mRNA regulatory axis. The results also provide possible understandings on the roles of circRNAs in host-virus interactions and will facilitate research studies on SARS-CoV-2 infection and pathogenesis in the future.

Fig 1. Using circRNA based therapeutics to mitigate cytokine storm syndrome induced by SARS-CoV-2.

Fig 1

Materials and methods

Data acquisition and processing

The Gene Expression Omnibus (GEO) [28] (https://www.ncbi.nlm.nih.gov/geo/), a database supported by the National Center for Biotechnology Information (NCBI) at the National Library of Medicine (NLM) was used to access the microarray and RNA-sequencing datasets that contains circRNA, miRNA and mRNA expression profiles of SARS-CoV-2 infected patients at various stages (Table 1) (Fig 2). GEO accepts high-throughput gene expression profiles (both raw and processed data) along with sample characteristics, methodology, and experimental research design [29]. Two circRNA datasets including GSE166552 [17] and PRJCA002617 [30] were retrieved after comprehensive screening. Six miRNA datasets including [27, 3135] were screened. Moreover, fifteen datasets of mRNA expression profiles were retrieved including GSE19137, GSE166552, PRJCA002617, [32, 33, 3645] datasets. We also downloaded datasets from national genomic data center (https://ngdc.cncb.ac.cn/). As the present study does not involve human subjects and due to free availability of data in the GEO database, neither ethical approval nor informed consent was required.

Table 1. Datasets used for retrieving expression profiles of circRNAs, miRNAs and mRNAs.

Accession no/ Study details circRNA/ miRNA/ mRNA Sample Source Total dysregulated (n) Up-regulated Down-regulated
GSE166552 CircRNA Whole Blood Samples 70 30 40
PRJCA002617 CircRNA Lung Tissue Samples 31 12 19
[31] miRNA Blood Samples Nasopharyngeal Samples 8 1 7
[27] miRNA Lung Tissue Samples 1 - 1
[32] miRNA Blood Samples Nasopharyngeal Samples 112 43 69
[33] miRNA Blood Samples 6 3 3
[34] miRNA Lung Tissue Samples 6 2 4
[35] miRNA Lung Tissue Samples 10 5 5
GSE166552 mRNA Blood Samples 25 11 14
GSE19137 mRNA Lung Tissue Samples 171 108 63
PRJCA002617 mRNA Lung Tissue Samples 30 16 14
[36] mRNA Blood Samples 11 11 -
[37] mRNA Blood Samples 6 6 -
[38] mRNA Blood Samples 6 6 -
[39] mRNA Blood Samples 2 2 -
[40] mRNA Lung Tissue Samples 8 8 -
[46] mRNA Blood Samples 4 4 -
[41] mRNA Blood Samples 3 3 -
[42] mRNA Blood Samples Nasopharyngeal Samples 4 4 -
[43] mRNA Blood Samples 14 14 -
[32] mRNA Blood Samples Nasopharyngeal Samples 3 3 -
[44] mRNA Nasopharyngeal Samples 6 6 -
[45] mRNA Blood Samples 8 8 -

Fig 2. Flow chart of the approach utilized in the present study for the construction of SARS-CoV-2 related circRNA-miRNA-mRNA regulator network.

Fig 2

The GSE166552 dataset included 06 samples (03 SARS-CoV-2 positive and 03 controls). The PRJCA002617 dataset included 24 samples (12 SARS-CoV-2 positive and 12 controls). McDonald et al., dataset included 45 samples (25 SARS-CoV-2 infected patient samples and 20 healthy controls). The GSE19137 dataset included 21 samples (03 negative and 18 positive for SARS-CoV). Chow et al., dataset included 249 samples (147 SARS-CoV-2 infected samples and 102 controls). Dhar et al., dataset included 2157 samples (including 915 severe COVID-19 patients). Liu et al., dataset contained 40 samples in his study (including 13 severe COVID-19 patients). Farr et al., dataset included 20 samples (10 COVID-19 patients and 10 age and gender matched healthy controls). Li et al., dataset included 14 samples (10 COVID-19 patients and 4 healthy donors). Huang et al., dataset comprised of 41 samples (including 13 severe COVID-19 patients). Chi et al., dataset included 70 SARS-CoV-2 infected patients, 04 convalescent cases and 04 healthy controls. Lin et al., dataset included 334 samples in their study (including 23 severe COVID-19 patient samples). Chen et al(b)., dataset included 21 samples (including 11 severe COVID-19 patient samples). Chen et al(c)., dataset study contained 29 samples (including 14 severe COVID-19 patient samples). Blenco Melo et al., included 48 samples (24 SARS-CoV-2 positive samples and 24 negative samples). Del Velle et al., dataset included a total of 1484 samples (1097 positive for SARS-CoV-2 infection and 387 controls). Qin et al., dataset comprised of 452 samples in their study (including 286 severe COVID-19 patient samples). Yang et al., dataset included 50 samples (including 36 severe COVID-19 patient samples).

Tools for the prediction of circRNA, miRNA and mRNA targets

For the prediction of circRNA targets by using miRNA as an input search, we used different comprehensive databases including CircBank, CircInteractome and RNAInter v4.0 web tools (Table 2). CircBank (http://www.circbank.cn/) is a comprehensive, publicly available, functionally annotated human circRNAs database containing information of about 140,000 circRNAs from many different sources [47]. The Users can access information regarding conservation status, miRNA targets as well as protein coding potential of query circRNAs [47]. CircInteractome (https://circinteractome.nia.nih.gov/) is a readily accessible web tool for mapping miRNAs and protein-binding sites on junctions as well as junction-flanking sequences of human circRNAs [48]. RNA Interactome Database, RNAInter v4.0 (http://www.rnainter.org/) is a comprehensive RNA-associated interactome platform containing information of more than 41 million interactions of cellular RNAs in 154 species with evidence from both computational and experimental sources [49].

Table 2. List of all softwares and tools utilized in the current study.

For the prediction of miRNA/ mRNA targets by using mRNAs/miRNAs as an input search, we used databases including miRDB, miRWalk 2.0, miRTarBase, and TargetScan 7.0. miRDB (http://mirdb.org/), is an integrative, freely accessible, open platform for the prediction of miRNA targets. miRNA-target interactions with scores ≥80.0 were considered relevant, statistically significant and with higher confidence in the interactions whereas miRNA-target interactions with scores ≤80.0 were considered not relevant. By utilizing high-throughput experimental data, miRDB predicts miRNA targets in five species along with integrative analysis of gene ontology (GO) data [50]. miRWalk 2.0 (http://mirwalk.umm.uni-heidelberg.de/) provides information of more than 949 million computationally predicted as well as experimentally validated miRNA-mRNA interactions. In order to ensure reliability and accuracy of forecast results, miRWalk 2.0 incorporates 12 algorithms for prediction including miRWalk, mirbridge, Targetscan, Microt4, PITA, Pictar2, RNAhybrid, RNA22, miRNAMap, miRanda, miRMap and miRDB [51]. Cut-off value with a binding score of > 0.95 was considered as a screening threshold. miRTarBase (https://miRTarBase.cuhk.edu.cn/~miRTarBase/miRTarBase_2022/php/index.php) is a manually curated database containing information of more than 360,000 experimentally validated miRNA-mRNA interactions [52]. miRNA-mRNA interactions have been validated experimentally using microarray, CLIP-seq technology, reporter assays, high through-put sequencing and western blot experiments [52]. All the targets identified via miRTarBase were selected for further analysis. TargetScan v7.0 (http://www.targetscan.org/vert_80/), a flexible web based tool, predicts sequence based effective regulatory targets of miRNAs by incorporating 14 different features [53]. Conservation aggregate score of > 0.80 was considered as selection criteria as this score provides low false discovery rates. An overlap in at least two databases was used as filtering criteria for prioritizing and considering potential candidate targets. Previous comparative studies conducted on miRNA target prediction programs suggested that no program performed consistently superior to all others. Indeed, it has become a common practice for researchers to look at predictions produced by different miRNA-target prediction programs and focus on their intersection which might enhances the performance of analyses as well as improve prediction precision. The differences between algorithms are mostly seen in their respective weaknesses, i.e., the subset of false positives. For that reason, the fundamental motivation to focus selectively on the shared prediction by two algorithms is to eliminate false positives while preserving the vast majority of true positive RNAs. Therefore, conclusively, predictions are much more reliable when two or more prediction algorithms are combined, and the minimal loss of true positives are greatly outweighed by the removal of false positives. Selection criteria, threshold and prediction scores for each database were selected on the basis of their previously reported relationship with low false discovery rate and high accuracy in experimental validation studies via PCR and Luciferase assays.

Data preprocessing and identification of differentially expressed circRNAs, miRNAs, and mRNAs

Background noise correction and quantile normalization of preliminary data were performed. Literature mining and R-base statistical software, GEO2R was utilized for examining the raw gene expression data as well as for the analysis of differential expression profiles of miRNAs, circRNAs and mRNAs. For the datasets retrieved from GEO database, we have utilized GEO2R tool which uses force normalization by applying quantile normalization to the expression data making all selected samples having identical value distribution. For determining whether selected samples were suitable for differential expression analysis, we checked distribution of samples by observing the median-centered values. Median-centered values are generally indicative that the data are normalized and cross-comparable. In summary, data preprocessing was done via log2 transformation, quantile normalization and base line transformation using the median of the samples. The expression fold change was expressed as base-2 logarithm of FC (log2FC) to normalize the expression values obtained from different platforms. For the calculation of false discovery rate and p-value, the GEO2R inbuilt methods were utilized. Differentially expressed genes were considered up-regulated if they met the cutoff criteria of adjusted P < 0.05 and |logFC| > = 1. For down-regulated ones, logFC < = -1 was considered. LogFC means Log2-fold change between two experimental conditions or two groups of Samples. Next, an interactive Venn diagram drawing tool, Venny 2.1.0 (https://bioinfogp.cnb.csic.es/tools/venny/) was used to generate Venn diagram to find the intersection among circRNAs, miRNAs, and mRNAs datasets [64].

Previous studies conducted on analysis of RNAs and their targets suggested that no program performed consistently superior to all others. Indeed, it has become a common practice for researchers to look at predictions produced by prediction programs and focus on common findings which might enhances the performance of analyses as well as improve prediction precision. The algorithms mostly agree on highly expressed RNAs, however, in many cases, algorithm-specific false positives with high read counts are predicted, which is resolved by using the shared output from two (or more) algorithms.

Pathway and functional enrichment analysis

The Database for Annotation, Visualization and Integrated Discovery database (DAVID version 6.8; https://david.ncifcrf.gov/), a comprehensive knowledge-base functional classification and agglomeration algorithm was used to perform KEGG (Kyoto Encyclopedia of Genes and Genomes) pathway and GO analysis [61]. In order to increase reliability of results, DAVID incorporates 14 annotation categories including BioCarta Pathways, Swiss-Prot Keywords, Molecular Function, cellular components, KEGG Pathways, Biological Process, UniProt Sequence Features, BBID Pathways, SMART Domains, PIR SuperFamily Names, and InterPro Domains along with NIH Genetic Association DB. A p-value less than 0.05 (≤ 0.05) was considered to indicate a statistically significant difference [61]. KEGG is a manually curated bioinformatics resource for deciphering high-level cellular and organism-level functions [65].

Establishment of PPI networks and module analysis

In order to examine and explore the relationship and association among the differentially expressed genes from the retrieved datasets, we constructed a protein-protein interaction (PPI) network by utilizing the STRING webserver (https://string-db.org) [57]. STRING database currently covers more than 9 million proteins from 2,031 organisms. It constructs a PPI network on the basis of direct physical or indirect functional associations. Differentially expressed genes were imported in to STRING database. Afterwards, Cytoscape (https://cytoscape.org/), an open source bioinformatics resource was used to analyze and visualize the molecular interaction networks as well as hub genes via importing the obtained source files from STRING [58]. A confident interaction score ≥0.4 was fixed as cutoff standard. Moreover, the cytoHubba plug-in in Cytoscape was used to search the list of hub genes from the PPI network with node degrees [60]. In addition, via using MCODE plug-in, key modules were then screened and assessed from the PPI network [59].

Construction of circRNA–miRNA–mRNA network

A circRNA–miRNA–mRNA regulatory network was also constructed by using Cytoscape software.

Statement

All materials and methods were performed in accordance with the relevant guidelines.

Results

Differentially expressed circRNAs

GEO2R along with data mining tools were utilized to generate differentially expressed circRNA, miRNA and mRNA profiles. Two SARS-CoV-2 related circRNA datasets including GSE166552 and PRJCA002617 were retrieved after comprehensive screening. By analyzing the data using GEO2R, differentially expressed circRNAs were identified. A total of 70 dysregulated circRNAs were identified from GSE166552 dataset. In addition, a total of 31 dysregulated circRNAs were identified from PRJCA002617 dataset. Comprehensive analysis of two datasets revealed a total of 101 differentially expressed circRNAs (Table 3) (Fig 3).

Table 3. List of count of differentially expressed RNAs and their predicted targets.

Datasets Dysregulated circRNAs/miRNAs/mRNAs Predicted Targets
Up-regulated Down-regulated circRNAs miRNAs mRNA
GSE166552 30 circRNAs 40 circRNAs _ 4316 704000
PRJCA002617 12 circRNAs 19 circRNAs _ 1516
McDonald et al., 2021 1 miRNA 7 miRNAs 38937 _ 77722
Demirci et al., 2021 5 miRNAs 5 miRNAs _
Farr et al., 2021 43 miRNAs 69 miRNAs _
Li et al., 2020 3 miRNAs 3 miRNAs _
Chow et al., 2020 2 miRNAs 4 miRNAs _
Arora et al., 2020 1 miRNAs _
GSE19137 108 mRNAs 63 mRNAs 858423 5109 _
GSE166552 11mRNAs 14 mRNAs _
PRJCA002617 16 mRNAs 14mRNAs _
Chi et al., 2020 11mRNAs _ _
Chen et al., 2020b 5 mRNAs 1 mRNAs _
Lin et al., 2020 6 mRNAs _
Chen et al., 2020c 2 mRNAs _ _
Blanco-Melo et al., 2020 8 mRNAs _ _
Liu et al., 2020 4 mRNAs _ _
Del Valle et al., 2020 3 mRNAs _ _
Qin et al., 2020 4 mRNAs _ _
Yang et al., 2020 14 mRNAs _
Farr et al., 2021 3 mRNAs _ _
Dhar et al., 2021 6 mRNAs _ _
C. Huang et al., 2020 8 mRNAs _ _

Fig 3. Venn diagram of overlapped differentially expressed circRNAs among circRNAs of circRNA datasets, miRNA datasets and mRNA datasets.

Fig 3

a) Overlapped differentially expressed circRNAs among circRNAs of circRNA datasets, miRNA datasets and mRNA datasets (whole genes). b) Overlapped differentially expressed circRNAs among circRNAs of circRNA datasets, miRNA datasets and mRNA datasets (cytokine storm related mRNAs).

Differentially expressed miRNAs

For the prediction of differentially expressed miRNAs, GEO database and data mining tools were utilized. Six different miRNA datasets including McDonald et al., 2021, Arora et al., 2020, Farr et al., 2021, Li et al., 2020a, Chow et al., 2020 and Demirci et al., 2021 were screened. Findings revealed 112 dysregulated miRNAs in Farr et al., 2021 dataset. Dataset of Demirci et al., 2021, revealed 10 dysregulated miRNAs. In another dataset McDonald et al., 2021, 8 dysregulated miRNAs were retrieved. In another dataset of Li et al., 2020, 6 dysregulated miRNAs were retrieved. In addition, Arora et al., 2020 dataset revealed 1 dysregulated miRNA. Furthermore, a dataset of Chow et al., 2020, revealed 6 dysregulated miRNAs. Comprehensive analysis of six different miRNA datasets revealed 143 differentially expressed miRNAs.

Following that, the target genes of differentially expressed miRNAs were retrieved from miRDB, miRWalk 2.0, miRTarBase, and TargetScan 7.0 web-servers. Results revealed 77722 target genes for differentially expressed miRNAs. Further analysis revealed 38937 circRNAs have binding sites for respective differentially expressed miRNAs.

Differentially expressed mRNA

Fifteen different datasets of mRNA expression profiles were retrieved from the GEO database and data mining tools. Datasets includes GSE19137, GSE166552, PRJCA002617, Chi et al., 2020, Lin et al., 2020, Chen et al., 2020a, Chen et al., 2020b, Blanco-Melo et al., 2020, Liu et al., 2020, Del Valle et al., 2020, Qin et al., 2020, Yang et al., 2020, Farr et al., 2021, Dhar et al., 2021and Huang et al., 2020b. GSE19137 dataset revealed 171 dysregulated mRNAs. Another dataset PRJCA002617 revealed 30 dysregulated mRNAs. 25 dysregulated mRNAs were identified in GSE166552 dataset. Dataset of Chi et al., 2020 revealed 11 dysregulated mRNAs. Another dataset of Lin et al., 2020 revealed 6 dysregulated mRNAs. 6 dysregulated mRNAs were identified in Chen et al., 2020a dataset. Chen et al., 2020b dataset revealed 2 dysregulated mRNAs. In addition, 8 dysregulated mRNAs were identified in Blanco-Melo et al., 2020 dataset. Liu et al., 2020 dataset revealed 4 dysregulated mRNAs. Furthermore, another dataset Del Valle et al., 2020 revealed 3 dysregulated mRNAs. Qin et al., 2020 dataset revealed 4 dysregulated mRNAs. In addition Yang et al., 2020, dataset revealed 14 dysregulated mRNAs. In another dataset by Farr et al., 2021, findings revealed 3 dysregulated mRNAs. In addition, Dhar et al., 2021 dataset revealed 6 dysregulated mRNAs. Furthermore, a dataset of Huang et al., 2020b revealed 8 dysregulated mRNAs. Comprehensive analysis of fifteen different datasets revealed a total of 301 differentially expressed mRNAs.

Target miRNAs of differentially expressed circRNAs

Target analysis of differentially expressed circRNAs was performed. GSE166552 dataset revealed a total of 4316 miRNA targets having binding sites on differentially expressed circRNAs. PRJCA002617 dataset revealed a total of 1516 miRNAs targets having binding sites on differentially expressed circRNAs. Comprehensive analysis of two datasets revealed 5832 miRNAs targets having binding sites on differential expressed circRNAs.

Target mRNAs of predicted miRNAs

Comprehensive analysis of 5832 miRNAs targets having binding sites on differential expressed circRNAs revealed 704000 genes having binding sites for respective miRNAs.

Target mRNAs of differentially expressed miRNAs

mRNA target analysis of differentially expressed miRNAs in McDonald et al., 2021 dataset, Demirci et al., 2021, Farr et al., 2021 dataset, Li et al., 2020 dataset, Chow et al., 2020 dataset, and Arora et al., 2020 dataset revealed 77722 target genes.

Target circRNAs of differentially expressed miRNAs

Comprehensive analysis of differentially expressed miRNAs in McDonald et al., 2021 dataset, Demirci et al., 2021, Farr et al., 2021 dataset, Li et al., 2020 dataset, Chow et al., 2020 dataset, and Arora et al., 2020 dataset revealed 38937 target circRNAs.

Target miRNAs of differentially expressed mRNAs

miRNA target analysis of differentially expressed mRNAs from GSE19137, GSE166552, PRJCA002617, Chi et al., 2020, Lin et al., 2020, Chen et al., 2020a, Chen et al., 2020b, Blanco-Melo et al., 2020, Liu et al., 2020, Del Valle et al., 2020, Qin et al., 2020, Yang et al., 2020, Farr et al., 2021, Dhar et al., 2021and Huang et al., 2020b datasets revealed a total of 5109 miRNAs against differentially expressed mRNAs.

Target CircRNAs of predicted miRNAs

Comprehensive analysis of 5109 predicted miRNAs against differentially expressed mRNAs revealed 858423 circRNAs having binding sites for respective miRNAs.

Analysis of SARS-CoV-2 induced cytokine storm related circRNA-miRNA-mRNA Axis

Previous findings have revealed that research on therapeutic strategies which have the potential to counteract multiple cytokines and related signaling pathways involved in COVID-19 is the need of the hour to capitalize promising therapeutic approach. Here we analyzed 12 datasets in which authors have evaluated and studied cytokine expression profiles and signatures induced by SARS-CoV-2 (Table 4). We wanted to retrieve those circRNAs which can inhibit maximum number of cytokines induced by SARS-COV-2. Comprehensive analysis of datasets revealed a total of 74 differentially expressed mRNAs, all of which were found to be upregulated. After removing duplicates, 32 mRNAs were found to be dysregulated. miRNA target analysis of differentially expressed 32 mRNAs (IL-1β, IL2, IL4, IL-6, IL-7, IL-8, IL10, IL-12, IL-13, IL-17, IL-18, IL23, IL33, IL-37, IL-38, TNF-α, IFN-γ, CCL2, CXCL6, CXCL8, CXCL10, IP-10, MIP-1A, MIP1-B, PDGF, MCP1, GM-CSF, M-CSF, G-CSF, FGF, HGF, TGF-β) revealed a total of 262 miRNAs against differentially expressed mRNAs. Comprehensive analysis of 262 predicted miRNAs against differentially expressed 32 mRNAs revealed 99419 circRNAs having binding sites for respective miRNAs.

Table 4. Datasets used for the analysis of SARS-CoV-2 related cytokines.

Genes Study 1 Study 2 Study 3 Study 4 Study 5 Study 6 Study 7 Study 8 Study 9 Study 10 Study 11 Study 12
up-regulated down-regulated up-regulated down-regulated up-regulated down-regulated up-regulated down-regulated up-regulated down-regulated up-regulated down-regulated up-regulated down-regulated up-regulated down-regulated up-regulated down-regulated up-regulated down-regulated up-regulated down-regulated up-regulated down-regulated
IL-1β  _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _
IL-2 _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _
IL-4 _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _
IL-6 _ _ _ _ _ _ _ _ _ _ _ _ _ _
IL-7 _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _
IL-8 _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _
IL-10 _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _
IL-12 _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _
IL-13 _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _
IL-17 _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _
IL-18 _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _
IL-23 _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _
IL-33 _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _
 IL-37 _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _
IL-38 _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _
TNF-α _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _
IFN-γ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _
CCL2 _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _
CXCL6 _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _
CXCL8 _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _
CXCL10 _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _
 IP-10 _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _
MIP-1A _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _
MIP1-B _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _
PDGF _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _
MCP1 _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _
 GM-CSF _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _
M-CSF _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _
G-CSF _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _
FGF _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _
HGF _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _
TGF-β  _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _
[45] [39] [38] [46] [42] [32] [44] [41] [40] [36] [43] [37]

Common circRNA-miRNA-mRNA pairs among circRNA, miRNA and mRNA datasets

Analysis of common circRNAs among circRNA, miRNA and mRNA datasets revealed two circRNAs including hsa_circ_0080942 and hsa_circ_0080135 (Fig 3). The two filtered circRNAs have binding sites for 86 miRNAs. These 86 miRNAs have binding sites for 15 cytokine storm related mRNAs including IL-1β, IL-7, IL-10, IL-12B, IL-13, IL-17A, IL-33, IFN-γ, CCL2, CXCL6, CXCL8, CXCL10, MIP, FGF2, FGF14.

Construction of circRNA-miRNA-mRNA networks

The circRNA-miRNA-mRNA network of hsa_circ_0080942 and hsa_circ_0080135 was visualized using the Cytoscape software. The hsa_circ_0080942 network included 47 miRNAs forming 88 pairs of circRNA-miRNA-mRNA axis. For instance, hsa_circ_0080942 is the ceRNA of hsa-miR-1183 targeting MIP, CXCL8, CXCL10, IL33, IL1B, IL10, IL17A, IL12B. Furthermore, hsa_circ_0080942 is the ceRNA of hsa-miR-486-3p targeting IL33, IL13, IL1B and IL7. The hsa_circ_0080135 network included 39 miRNAs forming 77 pairs of circRNA-miRNA-mRNA axis. For instance, hsa_circ_0080135 is the ceRNA of hsa-miR-885-3p targeting IL12B, IL1B, IL33, CXCL10 and MIP. Furthermore, hsa_circ_0080135 is the ceRNA of hsa-miR-769-3p targeting IL12B, IFNG, CXCL6 and CXCL8 (Fig 4) (Table 5).

Fig 4. The SARS-CoV-2 induced cytokine storm related circRNA-miRNA-mRNA network visualized using Cytoscape software.

Fig 4

The circRNA-miRNA-mRNA network contains 81 nodes and 205 edges.

Table 5. SARS-CoV-2 induced cytokine storm related circRNA-miRNA-mRNA regulatory axis.

CircRNA Parent Gene miRNA mRNA
hsa_circ_0080942 PCLO hsa-miR-1183 MIP/CXCL8/CXCL10/IL33/IL1B/IL10/IL17A/IL12B
hsa-miR-486-3p IL33/IL13/IL1B/IL7
hsa-miR-769-3p IL12B/IFNG/CXCL6/CXCL8
hsa-miR-637 IL33/IL10/MIP
hsa-miR-1265 IL1B/IL33/CXCL6
hsa-miR-654-3p IL17A/IL33/MIP
hsa-miR-665 IL17A/IL33/IL12B
hsa-miR-346 IL13/IL10/MIP
hsa-miR-1258 IL12B/IL1B/IL33
hsa-miR-645 IL12B/IL13/IL1B
hsa-miR-1303 IL12B/IL10/MIP
hsa-miR-198 IL33/MIP
hsa-miR-614 IL33/MIP
hsa-miR-635 IL33/MIP
hsa-miR-331-3p IL33/IFNG
hsa-miR-557 IL33/IFNG
hsa-miR-622 IL17A/MIP
hsa-miR-1299 IL17A/IL7
hsa-miR-296-5p IL13/MIP
hsa-miR-609 IL12B/IL33
hsa-miR-1200 IL12B/IL13
hsa-miR-1208 IL12B/IFNG
hsa-miR-663b IL10/IFNG
hsa-miR-1224-3p MIP
hsa-miR-513a-5p MIP
hsa-miR-636 MIP
hsa-miR-647 MIP
hsa-miR-1290 IL7
hsa-miR-661 IL33
hsa-miR-578 IL1B
hsa-miR-610 IL1B
hsa-miR-671-5p IL1B
hsa-miR-518a-5p IL17A
hsa-miR-527 IL17A
hsa-miR-1253 IL13
hsa-miR-1294 IL13
hsa-miR-558 IL13
hsa-miR-583 IL13
hsa-miR-1264 IL12B
hsa-miR-507 IL12B
hsa-miR-571 IFNG
hsa-miR-924 IFNG
hsa-miR-1289 CXCL6
hsa-miR-450b-3p CXCL10
hsa-miR-135b-5p CXCL10
hsa-miR-3934-3p FGF14
hsa-miR-3064-5p IL1B
hsa_circ_0080135 TNS3 hsa-miR-885-3p IL12B/IL1B/IL33/CXCL10/MIP
hsa-miR-486-3p IL33/IL13/IL1B/IL7
hsa-miR-326 IL13/CXCL8/CXCL10/MIP
hsa-miR-769-3p IL12B/IFNG/CXCL6/CXCL8
hsa-miR-637 IL33/IL10/MIP
hsa-miR-638 IL1B/IL33/CXCL10
hsa-miR-654-3p IL17A/IL33/MIP
hsa-miR-665 IL17A/IL33/IL12B
hsa-miR-892b IL17A/IL10/MIP
hsa-miR-1231 IL13/IL17A/CCL2
hsa-miR-346 IL13/IL10/MIP
hsa-miR-146b-3p IL10/CXCL8/MIP
hsa-miR-1203 IL10/CXCL10/MIP
hsa-miR-198 IL33/MIP
hsa-miR-635 IL33/MIP
hsa-miR-1200 IL12B/IL13
hsa-miR-1208 IL12B/IFNG
hsa-miR-663b IL10/IFNG
hsa-miR-330-5p CXCL8/MIP
hsa-miR-512-5p CXCL8/MIP
hsa-miR-1224-3p MIP
hsa-miR-647 MIP
hsa-miR-1290 IL7
hsa-miR-661 IL33
hsa-miR-610 IL1B
hsa-miR-646 IL1B
hsa-miR-671-5p IL1B
hsa-miR-558 IL13
hsa-miR-1184 IL12B
hsa-miR-581 IL12B
hsa-miR-361-3p IFNG
hsa-miR-924 IFNG
hsa-miR-1289 CXCL6
hsa-miR-450b-3p CXCL10
hsa-miR-3064-5p IL1B
hsa-miR-4446-3p IL1B
hsa-miR-4700-5p IL1B
hsa-miR-5787 IL1B
hsa-miR-1226-3p FGF2

KEGG pathway and functional enrichment analysis

DAVID was used to conduct a KEGG pathway enrichment analysis to gain a better understanding of the differentially expressed genes’ function (Fig 5) (Table 6). In order to screen core and hub genes as well as physical and functional associations, 203 differentially expressed genes were imported to STRING web-based tool. These 203 differentially expressed genes represent the results of the mRNA datasets analyzed in the current manuscript. The threshold condition was a confidence score ≥0.4. The results of analyzed data were then imported into Cytoscape for visualization analysis, and node connectivity was calculated to screen for the central node (hub genes) of the network. Finally the relationship between hub genes and prioritized circRNAs were determined and analyzed. There were 203 nodes and 657 edges in the PPI network. The cytoHubba plug-in in Cytoscape was used to search the list of top 10 genes from the PPI network with node degrees indicating hub DEGs, including STAT1, RSAD2, IFIT1, IFIT3, IFIT2, DDX58, OAS2, MX2, IFI44 and IFI44L (Fig 6). Module analysis using MCODE plug in revealed 6 modules; module 1 containing 25 nodes and 272 edges, module 2 containing 6 nodes and 11 edges, module 3 containing 5 nodes and 7 edges, module 4 containing 5 nodes and 3 edges, module 5 containing 3 nodes and 3 edges and module 6 containing 3 nodes and 3 edges.

Fig 5. Gene ontology analysis of differentially expressed genes.

Fig 5

Top GO terms with lowest P-values in cellular component, molecular function, and biological process were shown, respectively.

Table 6. KEGG analysis of 15 cytokine storm related genes.

Sr. No KEGG Pathway Enrichment Score P value Cytokines Count
1 Chemokine signaling pathway 4.33 4.6E-3 4
2 Inflammatory bowel disease (IBD) 3.82 7.2E-8 6
3 Rheumatoid arthritis 3.82 3.6E-7 6
4 Toll-like receptor signaling pathway 3.82 9.1E-4 4
5 NOD-like receptor signaling pathway 3.82 4.8E-3 3
6 TNF signaling pathway 3.44 1.7E-2 3
7 RIG-I-like receptor signaling pathway 3.44 7.4E-3 3
8 Herpes simplex infection 3.44 4.4E-3 4
9 Influenza A 3.44 3.6E-7 7

Fig 6. The cytoHubba plug-in in Cytoscape was used to search the list of top 10 genes from the PPI network with node degrees indicating hub differentially expressed genes, including STAT1, RSAD2, IFIT1, IFIT3, IFIT2, DDX58, OAS2, MX2, IFI44 and IFI44L.

Fig 6

Pharmacogenomics analysis for hub genes

By exploring the website PharmGkb, genes indirectly targeted by two prioritized circRNAs were selected for Pharmacogenomics analysis to find some potential drugs. The results revealed that HMG-CoA reductase inhibitors (target: STAT1), simvastatin (target: STAT1), atorvastatin (target: STAT1), aspirin (target: STAT1), pravastatin (target: STAT1), rosuvastatin (target: STAT1), clomipramine (target: MIP), Imipramine (target: MIP), Mercaptopurine (target: MIP), trimipramine (target: MIP), diosmectite (target: CXCL10), canakinumab (target: IL-1B), anakinra (target: IL-1B), secukinumab (target: IL-17A), ixekizumab (target: IL-17A), and chloroquine (FGF2) might serve as potential therapeutic options for SARS-CoV-2 infection (Table 7). Many of these drugs have been approved by FDA against COVID-19 and previously been found to be effective in mitigating the effect of SARS-CoV-2, further increasing the reliability of current study results. Study of Bergqvist et al., revealed negative association between Statin treatment and COVID-19 mortality [66]. Mercaptopurine, a purine analogue has been previously reported as a selective inhibitor of both MERS-CoV and SARS-CoV [67]. In another study, authors found that a tricyclic antidepressant trimipramine protected against SARS-CoV-2 induced cytopathic effect via inhibiting autophagy [68]. Moreover, Clomipramine was found to be effective in preventing neurological manifestations of SARS-CoV-2 Infection [69]. In a retrospective study, statins were found to have potential beneficial effects on mortality rates associated with SARS-CoV-2 infection [70]. Diosmectite, which is an aluminomagnesium silicate adsorbent clay has been recommended for managing COVID-19. Exposure of this drug inhibited CXCL10 secretion and NF-kappaB activation [71]. Moreover both anakinra (by blocking IL-1 receptor) and canakinumab (by blocking the IL-1 signaling) can potentially interrupt autoinflammatory loop during SARS-CoV-2 infection. Another drug Chloroquine has been reported to inhibit FGF2-induced mitogenic activity [72].

Table 7. Drug targets and their association with prioritized circRNAs during SARS-CoV-2 infection.

Drugs mRNAs miRNAs CircRNAs
Clomipramine Imipramine Mercaptopurine Trimipramine MIP hsa-miR-1183 hsa_circ_0080942
hsa-miR-637
hsa-miR-654-3p
hsa-miR-346
hsa-miR-1303
hsa-miR-198
hsa-miR-614
hsa-miR-635
hsa-miR-622
hsa-miR-296-5p
hsa-miR-1224-3p
hsa-miR-513a-5p
hsa-miR-636
hsa-miR-647
hmg coa reductase inhibitors STAT1
simvastatin
atorvastatin
aspirin
pravastatin
rosuvastatin
Diosmectite CXCL10 hsa-miR-1183 hsa_circ_0080942
hsa-miR-450b-3p
hsa-miR-135b-5p
Canakinumab Anakinra IL-1 B hsa-miR-1183 hsa_circ_0080942
hsa-miR-486-3p
hsa-miR-1265
hsa-miR-1258
hsa-miR-645
hsa-miR-578
hsa-miR-610
hsa-miR-671-5p
hsa-miR-3064-5p
Secukinumab Ixekizumab IL-17A hsa-miR-1183 hsa_circ_0080942
hsa-miR-486-3p
hsa-miR-654-3p
hsa-miR-665
hsa-miR-622
hsa-miR-1299
hsa-miR-518a-5p
hsa-miR-527
Chloroquine FGF2 hsa-miR-1226-3p hsa_circ_0080135

Multiple drugs approved right now for the treatment of SARS-CoV2 infection have targets been regulated by two prioritized circRNAs. Instead of using multiple drugs targeting multiple mRNAs, we can utilize single circRNA regulating multiple disease related mRNAs. We have also retrieved the Coronavirus disease-COVID-19 pathway from KEGG database with pathway ID: map05171. This pathway illustrates those cytokines that are part of cytokine syndrome induced during the SARS-CoV-2 infection. Further we have highlighted the target cytokines of prioritized miRNAs and circRNAs of current study to decipher the importance of future therapeutic avenues using circRNAs (Fig 7).

Fig 7. Pathway analysis of COVID-19 pathogenesis (KEGG pathway ID: map05171).

Fig 7

Highlighted genes are targets of miRNAs and indirect targets of two prioritized circRNAs.

Discussion

A number of studies have highlighted significant involvement of circRNA-miRNA-mRNA regulatory axis in signaling pathways of human diseases [24]. CircRNA, a type of highly conserved endogenous RNA, has been shown to operate as a "sponge" that absorbs matching miRNA by engaging with miRNA binding sites and therefore indirectly regulates gene expression [73]. In the current approach (Fig 2), we have systematically analyzed datasets to explore circRNA, miRNA, and mRNA expression profiles during SARS-CoV-2 infection. Findings of our study revealed differential expression profiles of circRNAs, mRNAs and miRNAs during SARS-CoV-2 infection. Functional analysis was performed along with construction of protein-protein interaction network and circRNA-miRNA-mRNA network. Final circRNA-miRNA-mRNA network was constructed based on cytokine storm related circRNAs forming a total of 165 circRNA-miRNA-mRNA pairs. Our investigation of the triple regulatory networks of circRNA-miRNA-mRNA revealed two circRNAs including hsa_circ_0080942 and hsa_circ_0080135 as a potential theranostic agents for SARS-CoV-2 infection. Further these results have shed light on the complex regulatory mechanism of circRNAs in SARS-CoV-2.

Analysis of miRNA targets of prioritized circRNAs revealed significant role of respective miRNAs in SARS-CoV-2 pathogenesis. In one of the study, the expression level of hsa-miR-135b-5 was found to be down-regulated in lung epithelial cells infected with SARS-CoV-2. The authors concluded that, lowering the expression level of host miRNAs is expected to make the respiratory epithelium more susceptible to infection where as increasing the expression levels of host miRNAs might mitigate coronavirus infection [34]. In another study, miR-8066 was found to be associated with cytokine storm which is one of the major COVID-19 problem [74]. Authors revealed that miR-8066 significantly impacted cytokine-cytokine receptor pathway. Moreover, miR-3934-3p have been found to down-regulate TGFBR1 and SMAD3 which are critical players for lung fibrosis and have been previously reported in SARS-CoV-related cases [74]. The work of Peng et al., revealed regulatory role of miR-486-5p in influenza virus replication. The authors proposed that designing miRNA-based therapies against viral infection might be a useful strategy as increased expression of miRNAs elicits effective antiviral defenses against influenza A viruses [75]. Sang et al., revealed that down-regulation of miR-637 was the causative factor of Pulmonary hypertension [76]. In another work, the authors found that suppressing the level of cellular miRNA hsa-miR-1258 enhanced viral particle production by 2.99 folds [77]. Another study revealed that Coxsackievirus A16 induced down-regulation of miR-1303 promoted the disruption of blood brain barrier integrity via miR-1303-MMP axis [78]. The work performed by Sung et al., revealed anti-HIV-1 activity of miR-198 via targeting cyclin T1 [79]. Bagasra et al., found down-regulation of has-miR-5787 in Zika virus infected neuronal cell line [80]. A number of other studies have revealed down-regulation of miRNA targets of prioritized circRNAs in viral infections and other diseases. Targeting circRNAs as a therapeutic approach might seems feasible strategy as single circRNA can target multiple miRNAs.

Further we also analyzed hub genes and cytokine storm related genes of prioritized circRNAs. Orumaa and co-authors revealed that severity of COVID-19 is linked to cytokine storm, which occurs when levels of inflammatory mediators such as IL-7, IL-10, and MIP are up-regulated [81]. Hassan et al., revealed the connection of IL-17 to critically sick patients infected with SARS-CoV-2 [82]. [83] study showed that over-expression of IL1B could be impacted by up-regulation of IRF8 and MYD88 [83]. The pro-inflammatory cytokine IL1B, which encodes IL-1, is one of the key mediators in inducing innate immune response-mediated inflammation in COVID-19 patients’ lungs. In one of the study, Gupta et al., showed that activation of the cytokines including CXCL6, CXCL8 and CXCL10 is a distinctive profile of cytokine response in COVID-19 patients [84]. In another study, authors found association between increased level of FGF2 and patients with severe COVID-19 [85]. The work performed by Donlan et al., discovered that IL-13 levels in severe COVID-19 patients requiring ICU and/or mechanical ventilation rose from day 5 to day 20 of illness. These findings suggest that IL-13 is a key component of the host’s response to SARS-CoV-2 infection and may be driving factor for severe illness [86]. A previous study found that seriously affected COVID-19 patients had an increased level of STAT1 and IRF9 [87]. Work of Giovannoni and coauthors revealed increased expression levels of RSAD2 in COVID-19 and found substantial correlation of RSAD2 with viral load [88]. Moreover another study revealed increased level of DDX58 in COVID-19-positive patients [89]. Another study found increased levels of IFI27 and OAS2 in COVID-19 patients [90].

Integrative analysis performed by Lu and coauthors revealed regulatory activities of circRNAs and their particular interaction with other RNAs via circRNA-miRNA-mRNA regulatory axis during Hantavirus infection [91]. In addition various recent study showed that circRNAs have been shown to bind to miRNAs and serve as natural miRNA sponges, influencing the activities of associated miRNAs and the gene expressions controlled by miRNAs [92]. Prioritized circRNAs includes hsa_circ_0080942 and hsa_circ_0080135. The hsa_circ_0080942 network included 47 miRNAs and 15 cytokine storm related genes forming 88 pairs of circRNA-miRNA-mRNA axis. For instance, hsa_circ_0080942 is the ceRNA of hsa-miR-1183 targeting MIP, CXCL8, CXCL10, IL33, IL1B, IL10, IL17A, IL12B. Furthermore, hsa_circ_0080942 is the ceRNA of hsa-miR-486-3p targeting IL33, IL13, IL1B and IL7. The hsa_circ_0080135 network included 39 miRNAs and 15 cytokine storm related genes forming 77 pairs of circRNA-miRNA-mRNA axis. For instance, hsa_circ_0080135 is the ceRNA of hsa-miR-885-3p targeting IL12B, IL1B, IL33, CXCL10 and MIP. Furthermore, hsa_circ_0080135 is the ceRNA of hsa-miR-769-3p targeting IL12B, IFNG, CXCL6 and CXCL8. Via targeting two prioritized circRNAs, maximum number of cytokines dysregulated during SARS-CoV-2 infection can be targeted.

Furthermore Pharmacogenomics analysis was performed to retrieve some potentials therapeutic options for SARS-CoV-2 infection. Many of these drugs were previously found to be effective in mitigating the effect of SARS-CoV-2. Study of Bergqvist et al., revealed negative association between Statin treatment and COVID-19 mortality [66]. Mercaptopurine, a purine analogue has been previously reported as a selective inhibitor of both MERS-CoV and SARS-CoV [67]. In another study, authors found that a tricyclic antidepressant trimipramine protected against SARS-CoV-2 induced cytopathic effect via inhibiting autophagy [68]. Moreover, Clomipramine was found to be effective in preventing neurological manifestations of SARS-CoV-2 Infection [69]. In a retrospective study, statins were found to have potential beneficial effects on mortality rates associated with SARS-CoV-2 infection [70].

Another important consideration is that there are variety of conceptually different approaches for inferring and analyzing these datasets. Many comparisons have been conducted to determine which one is most suitable and reliable. The problem is that the results of such technical comparisons depend crucially on the studied conditions, including; type of the data, number of samples, amount of noise, experimental design, type of the underlying interaction structure and how you are measuring the error. For this reason it is unlikely that there is one “right” method that fits all different biological, technical and experimental design conditions best. It is also highly unlikely that there is just one method that outperforms all others for all conditions. In the current study, the construction of circRNA/miRNA/mRNA regulatory networks and the prediction of therapeutic drugs were all relying on a series of bioinformatics algorithms and databases. Still a large number of experiments are needed to verify the accuracy of these prediction conclusions. In addition, in the choice of differentially expressed RNAs, the selection criteria with higher credibility are adopted. Most reliable and reasonable algorithms were selected, but random errors and selection bias cannot be avoided.

Previous studies have indicated that circRNA is a type of high-efficiency competing endogenous RNA (ceRNA) and operate as part of ceRNA regulatory networks. It can regulate the expression level of multiple target genes by exerting a miRNA sequestering effect. This work along with other recent studies suggests that by inhibiting disease related circRNAs might present a new generation of versatile and adjustable RNA therapeutics with significant potential.

Ongoing clinical trials for the treatment of COVID-19 have proposed different therapeutic options including various drugs, monoclonal antibodies, immunoglobulin therapy, convalescent plasma therapy and cell therapy. However, at present, effects, safety, and efficacy of current treatment strategies are still uncertain and therefore more prospective clinical studies are needed in the future for further evaluation [93, 94]. Research on therapeutic strategies which have the potential to counteract multiple cytokines and related signaling pathways involved in COVID-19 is the need of the hour to capitalize promising therapeutic approach. Targeting prioritized circRNAs might provide attractive treatment option. Since circRNA is an upstream regulator of miRNA and mRNA, it may be possible to develop a circRNA–miRNA–mRNA panel, possibly including the hsa_circ_0080942 and hsa_circ_0080135 described in this work, for clinical applications as potential theranostic agents in SARS-CoV-2 infection.

Data Availability

Availability of Data and Materials The authors declare that the data supporting the findings of this study are addressed within the article and confirm that all the datasets analyzed during the current study are accessible from the literature as well as from the GEO database (https://www.ncbi.nlm.nih.gov/gds/) with accession details (GSE166552, GSE19137, PRJCA002617, (McDonald, Enguita et al. 2021), (Arora, Singh et al. 2020), (Farr, Rootes et al. 2021), (Li, Hu et al. 2020), (Chow and Salmena 2020), (Demirci and Demirci 2021), (Chi, Ge et al. 2020), (Lin, Luo et al. 2020), (Chen, Wu et al. 2020), (Chen, Liu et al. 2020), (Blanco-Melo, Nilsson-Payant et al. 2020), (Li, Hu et al. 2020), (Del Valle, Kim-Schulze et al. 2020), (Qin, Zhou et al. 2020), (Yang, Shen et al. 2020), (Dhar, Vishnupriyan et al. 2021), and (Huang, Wang et al. 2020) datasets).

Funding Statement

The authors extend their appreciation to the Deputyship for Research & Innovation, Ministry of Education in Saudi Arabia for funding this research work through the project number 223202.

References

  • 1.Cella E, Benedetti F, Fabris S, Borsetti A, Pezzuto A, Ciotti M, et al. SARS-CoV-2 lineages and sub-lineages circulating worldwide: a dynamic overview. Chemotherapy. 2021:1–5. doi: 10.1159/000515340 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Shah VK, Firmal P, Alam A, Ganguly D, Chattopadhyay S. Overview of immune response during SARS-CoV-2 infection: lessons from the past. Frontiers in immunology. 2020;11:1949. doi: 10.3389/fimmu.2020.01949 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Hu B, Huang S, Yin L. The cytokine storm and COVID‐19. Journal of medical virology. 2021;93(1):250–6. doi: 10.1002/jmv.26232 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Azkur AK, Akdis M, Azkur D, Sokolowska M, van de Veen W, Brüggen MC, et al. Immune response to SARS‐CoV‐2 and mechanisms of immunopathological changes in COVID‐19. Allergy. 2020;75(7):1564–81. doi: 10.1111/all.14364 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Henzinger H, Barth DA, Klec C, Pichler M. Non-coding RNAs and SARS-related coronaviruses. Viruses. 2020;12(12):1374. doi: 10.3390/v12121374 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Shirahama S, Miki A, Kaburaki T, Akimitsu N. Long non-coding RNAs involved in pathogenic infection. Frontiers in Genetics. 2020;11:454. doi: 10.3389/fgene.2020.00454 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Skalsky RL, Cullen BR. Viruses, microRNAs, and host interactions. Annual review of microbiology. 2010;64:123–41. doi: 10.1146/annurev.micro.112408.134243 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Wang P. The opening of pandora’s box: An emerging role of long noncoding RNA in viral infections. Frontiers in immunology. 2019;9:3138. doi: 10.3389/fimmu.2018.03138 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Winterling C, Koch M, Koeppel M, Garcia-Alcalde F, Karlas A, Meyer TF. Evidence for a crucial role of a host non-coding RNA in influenza A virus replication. RNA biology. 2014;11(1):66–75. doi: 10.4161/rna.27504 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Fortes P, Morris KV. Long noncoding RNAs in viral infections. Virus research. 2016;212:1–11. doi: 10.1016/j.virusres.2015.10.002 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Girardi E, López P, Pfeffer S. On the importance of host microRNAs during viral infection. Frontiers in Genetics. 2018;9:439. doi: 10.3389/fgene.2018.00439 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Esteller M. Non-coding RNAs in human disease. Nature reviews genetics. 2011;12(12):861–74. doi: 10.1038/nrg3074 [DOI] [PubMed] [Google Scholar]
  • 13.Sullivan CS, Ganem D. MicroRNAs and viral infection. Molecular cell. 2005;20(1):3–7. doi: 10.1016/j.molcel.2005.09.012 [DOI] [PubMed] [Google Scholar]
  • 14.Tycowski KT, Guo YE, Lee N, Moss WN, Vallery TK, Xie M, et al. Viral noncoding RNAs: more surprises. Genes & development. 2015;29(6):567–84. doi: 10.1101/gad.259077.115 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Auvinen E. Diagnostic and prognostic value of MicroRNA in viral diseases. Molecular diagnosis & therapy. 2017;21(1):45–57. doi: 10.1007/s40291-016-0236-x [DOI] [PubMed] [Google Scholar]
  • 16.Chen L, Zhou Y, Li H. LncRNA, miRNA and lncRNA-miRNA interaction in viral infection. Virus Research. 2018;257:25–32. doi: 10.1016/j.virusres.2018.08.018 [DOI] [PubMed] [Google Scholar]
  • 17.Wu Y, Zhao T, Deng R, Xia X, Li B, Wang X. A study of differential circRNA and lncRNA expressions in COVID-19-infected peripheral blood. Scientific reports. 2021;11(1):1–14. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.He AT, Liu J, Li F, Yang BB. Targeting circular RNAs as a therapeutic approach: current strategies and challenges. Signal Transduction and Targeted Therapy. 2021;6(1):1–14. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Nahand JS, Jamshidi S, Hamblin MR, Mahjoubin-Tehran M, Vosough M, Jamali M, et al. Circular RNAs: new epigenetic signatures in viral infections. Frontiers in microbiology. 2020;11:1853. doi: 10.3389/fmicb.2020.01853 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Sun J, Li B, Shu C, Ma Q, Wang J. Functions and clinical significance of circular RNAs in glioma. Molecular cancer. 2020;19(1):1–18. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Mo Y, Liu Y, Lu A, Zhang H, Tang L. Role of circRNAs in viral infection and their significance for diagnosis and treatment. International Journal of Molecular Medicine. 2021;47(5):1–12. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Awan FM, Yang BB, Naz A, Hanif A, Ikram A, Obaid A, et al. The emerging role and significance of circular RNAs in viral infections and antiviral immune responses: possible implication as theranostic agents. RNA biology. 2021;18(1):1–15. doi: 10.1080/15476286.2020.1790198 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Su Q, Lv X. Revealing new landscape of cardiovascular disease through circular RNA-miRNA-mRNA axis. Genomics. 2020;112(2):1680–5. doi: 10.1016/j.ygeno.2019.10.006 [DOI] [PubMed] [Google Scholar]
  • 24.Rong D, Sun H, Li Z, Liu S, Dong C, Fu K, et al. An emerging function of circRNA-miRNAs-mRNA axis in human diseases. Oncotarget. 2017;8(42):73271. doi: 10.18632/oncotarget.19154 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Su Y, Yi Y, Li L, Chen C. circRNA-miRNA-mRNA network in age-related macular degeneration: from construction to identification. Experimental Eye Research. 2021;203:108427. doi: 10.1016/j.exer.2020.108427 [DOI] [PubMed] [Google Scholar]
  • 26.Yu C-Y, Kuo H-C. The emerging roles and functions of circular RNAs and their generation. Journal of biomedical science. 2019;26(1):1–12. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Arora S, Singh P, Dohare R, Jha R, Syed MA. Unravelling host-pathogen interactions: ceRNA network in SARS-CoV-2 infection (COVID-19). Gene. 2020;762:145057. doi: 10.1016/j.gene.2020.145057 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Edgar R, Domrachev M, Lash AE. Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic acids research. 2002;30(1):207–10. doi: 10.1093/nar/30.1.207 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Clough E, Barrett T. The gene expression omnibus database. Statistical genomics: Springer; 2016. p. 93–110. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Yang M, Qi M, Xu L, Huang P, Wang X, Sun J, et al. Differential host circRNA expression profiles in human lung epithelial cells infected with SARS-CoV-2. Infection, Genetics and Evolution. 2021;93:104923. doi: 10.1016/j.meegid.2021.104923 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.McDonald JT, Enguita FJ, Taylor D, Griffin RJ, Priebe W, Emmett MR, et al. Role of miR-2392 in driving SARS-CoV-2 infection. Cell reports. 2021;37(3):109839. doi: 10.1016/j.celrep.2021.109839 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Farr R, Rootes C, Rowntree L, Nguyen T, Hensen L, Kedzierski L, et al. Altered microRNA expression in COVID-19 patients enables identification of SARS-CoV-2 infection. 2021. doi: 10.1371/journal.ppat.1009759 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Li C, Hu X, Li L, Li Jh. Differential microRNA expression in the peripheral blood from human patients with COVID‐19. Journal of clinical laboratory analysis. 2020;34(10):e23590. doi: 10.1002/jcla.23590 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Chow JT-S, Salmena L. Prediction and analysis of SARS-CoV-2-targeting MicroRNA in human lung epithelium. Genes. 2020;11(9):1002. doi: 10.3390/genes11091002 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Demirci YM, Demirci MDS. Circular RNA–MicroRNA–MRNA interaction predictions in SARS-CoV-2 infection. Journal of Integrative Bioinformatics. 2021;18(1):45–50. doi: 10.1515/jib-2020-0047 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Chi Y, Ge Y, Wu B, Zhang W, Wu T, Wen T, et al. Serum cytokine and chemokine profile in relation to the severity of coronavirus disease 2019 in China. The Journal of infectious diseases. 2020;222(5):746–54. doi: 10.1093/infdis/jiaa363 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Lin L, Luo S, Qin R, Yang M, Wang X, Yang Q, et al. Long-term infection of SARS-CoV-2 changed the body’s immune status. Clinical Immunology. 2020;218:108524. doi: 10.1016/j.clim.2020.108524 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H, et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. The Journal of clinical investigation. 2020;130(5):2620–9. doi: 10.1172/JCI137244 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Chen L, Liu H, Liu W, Liu J, Liu K, Shang J, et al. Analysis of clinical features of 29 patients with 2019 novel coronavirus pneumonia. Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases. 2020;43:E005–E. doi: 10.3760/cma.j.issn.1001-0939.2020.0005 [DOI] [PubMed] [Google Scholar]
  • 40.Blanco-Melo D, Nilsson-Payant BE, Liu W-C, Uhl S, Hoagland D, Møller R, et al. Imbalanced host response to SARS-CoV-2 drives development of COVID-19. Cell. 2020;181(5):1036–45. e9. doi: 10.1016/j.cell.2020.04.026 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Del Valle DM, Kim-Schulze S, Huang H-H, Beckmann ND, Nirenberg S, Wang B, et al. An inflammatory cytokine signature predicts COVID-19 severity and survival. Nature medicine. 2020;26(10):1636–43. doi: 10.1038/s41591-020-1051-9 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Qin C, Zhou L, Hu Z, Zhang S, Yang S, Tao Y, et al. Dysregulation of immune response in patients with coronavirus 2019 (COVID-19) in Wuhan, China. Clinical infectious diseases. 2020;71(15):762–8. doi: 10.1093/cid/ciaa248 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Yang Y, Shen C, Li J, Yuan J, Wei J, Huang F, et al. Plasma IP-10 and MCP-3 levels are highly associated with disease severity and predict the progression of COVID-19. Journal of Allergy and Clinical Immunology. 2020;146(1):119–27. e4. doi: 10.1016/j.jaci.2020.04.027 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Dhar SK, Vishnupriyan K, Damodar S, Gujar S, Das M. IL-6 and IL-10 as predictors of disease severity in COVID-19 patients: results from meta-analysis and regression. Heliyon. 2021;7(2):e06155. doi: 10.1016/j.heliyon.2021.e06155 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The lancet. 2020;395(10223):497–506. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.Liu J, Li S, Liu J, Liang B, Wang X, Wang H, et al. Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients. EBioMedicine. 2020;55:102763. doi: 10.1016/j.ebiom.2020.102763 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.Liu M, Wang Q, Shen J, Yang BB, Ding X. Circbank: a comprehensive database for circRNA with standard nomenclature. RNA biology. 2019;16(7):899–905. doi: 10.1080/15476286.2019.1600395 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48.Dudekula DB, Panda AC, Grammatikakis I, De S, Abdelmohsen K, Gorospe M. CircInteractome: a web tool for exploring circular RNAs and their interacting proteins and microRNAs. RNA biology. 2016;13(1):34–42. doi: 10.1080/15476286.2015.1128065 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49.Kang J, Tang Q, He J, Li L, Yang N, Yu S, et al. RNAInter v4. 0: RNA interactome repository with redefined confidence scoring system and improved accessibility. Nucleic acids research. 2021. doi: 10.1093/nar/gkab997 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.Wang X. miRDB: a microRNA target prediction and functional annotation database with a wiki interface. Rna. 2008;14(6):1012–7. doi: 10.1261/rna.965408 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 51.Dweep H, Gretz N. miRWalk2. 0: a comprehensive atlas of microRNA-target interactions. Nature methods. 2015;12(8):697–. doi: 10.1038/nmeth.3485 [DOI] [PubMed] [Google Scholar]
  • 52.Huang H-Y, Lin Y-C-D, Li J, Huang K-Y, Shrestha S, Hong H-C, et al. miRTarBase 2020: updates to the experimentally validated microRNA–target interaction database. Nucleic acids research. 2020;48(D1):D148–D54. doi: 10.1093/nar/gkz896 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 53.Agarwal V, Bell GW, Nam J-W, Bartel DP. Predicting effective microRNA target sites in mammalian mRNAs. elife. 2015;4:e05005. doi: 10.7554/eLife.05005 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 54.Barrett T, Wilhite SE, Ledoux P, Evangelista C, Kim IF, Tomashevsky M, et al. NCBI GEO: archive for functional genomics data sets—update. Nucleic acids research. 2012;41(D1):D991–D5. doi: 10.1093/nar/gks1193 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 55.Huang H-Y, Lin Y-C-D, Cui S, Huang Y, Tang Y, Xu J, et al. miRTarBase update 2022: an informative resource for experimentally validated miRNA–target interactions. Nucleic acids research. 2022;50(D1):D222–D30. doi: 10.1093/nar/gkab1079 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 56.Chen Y, Wang X. miRDB: an online database for prediction of functional microRNA targets. Nucleic acids research. 2020;48(D1):D127–D31. doi: 10.1093/nar/gkz757 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 57.Snel B, Lehmann G, Bork P, Huynen MA. STRING: a web-server to retrieve and display the repeatedly occurring neighbourhood of a gene. Nucleic acids research. 2000;28(18):3442–4. doi: 10.1093/nar/28.18.3442 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 58.Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome research. 2003;13(11):2498–504. doi: 10.1101/gr.1239303 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 59.Saito R, Smoot ME, Ono K, Ruscheinski J, Wang P-L, Lotia S, et al. A travel guide to Cytoscape plugins. Nature methods. 2012;9(11):1069–76. doi: 10.1038/nmeth.2212 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 60.Chin C-H, Chen S-H, Wu H-H, Ho C-W, Ko M-T, Lin C-Y. cytoHubba: identifying hub objects and sub-networks from complex interactome. BMC systems biology. 2014;8(4):1–7. doi: 10.1186/1752-0509-8-S4-S11 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 61.Sherman BT, Tan Q, Collins JR, Alvord WG, Roayaei J, Stephens R, et al. The DAVID Gene Functional Classification Tool: a novel biological module-centric algorithm to functionally analyze large gene lists. Genome biology. 2007;8(9):1–16. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 62.Kanehisa M, Goto S. KEGG: kyoto encyclopedia of genes and genomes. Nucleic acids research. 2000;28(1):27–30. doi: 10.1093/nar/28.1.27 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 63.Thorn CF, Klein TE, Altman RB. PharmGKB: the pharmacogenomics knowledge base. Pharmacogenomics: Springer; 2013. p. 311–20. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 64.Oliveros J. Venny. An interactive tool for comparing lists with Venn’s diagrams. 2007–2015. 2016. [Google Scholar]
  • 65.Aoki KF, Kanehisa M. Using the KEGG database resource. Current protocols in bioinformatics. 2005;11(1):1.12. 1–1. 54. doi: 10.1002/0471250953.bi0112s11 [DOI] [PubMed] [Google Scholar]
  • 66.Bergqvist R, Ahlqvist VH, Lundberg M, Hergens M-P, Sundström J, Bell M, et al. HMG-CoA reductase inhibitors and COVID-19 mortality in Stockholm, Sweden: A registry-based cohort study. PLoS medicine. 2021;18(10):e1003820. doi: 10.1371/journal.pmed.1003820 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 67.Zhou Y, Hou Y, Shen J, Huang Y, Martin W, Cheng F. Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2. Cell discovery. 2020;6(1):1–18. doi: 10.1038/s41421-020-0153-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 68.Chen CZ, Xu M, Pradhan M, Gorshkov K, Petersen JD, Straus MR, et al. Identifying SARS-CoV-2 entry inhibitors through drug repurposing screens of SARS-S and MERS-S pseudotyped particles. ACS Pharmacology & Translational Science. 2020;3(6):1165–75. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 69.Nobile B, Durand M, Olié E, Guillaume S, Molès J, Haffen E, et al. Clomipramine could be useful in preventing neurological complications of SARS-CoV-2 infection. Journal of Neuroimmune Pharmacology. 2020;15(3):347–8. doi: 10.1007/s11481-020-09939-2 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 70.Peymani P, Dehesh T, Aligolighasemabadi F, Sadeghdoust M, Kotfis K, Ahmadi M, et al. Statins in patients with COVID-19: a retrospective cohort study in Iranian COVID-19 patients. Translational medicine communications. 2021;6(1):1–14. doi: 10.1186/s41231-021-00082-5 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 71.Poeta M, Cioffi V, Buccigrossi V, Nanayakkara M, Baggieri M, Peltrini R, et al. Diosmectite inhibits the interaction between SARS-CoV-2 and human enterocytes by trapping viral particles, thereby preventing NF-kappaB activation and CXCL10 secretion. Scientific reports. 2021;11(1):1–8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 72.Meini S, Giani T, Tascini C. Intussusceptive angiogenesis in Covid-19: hypothesis on the significance and focus on the possible role of FGF2. Molecular Biology Reports. 2020;47(10):8301–4. doi: 10.1007/s11033-020-05831-7 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 73.Bai S, Wu Y, Yan Y, Shao S, Zhang J, Liu J, et al. Construct a circRNA/miRNA/mRNA regulatory network to explore potential pathogenesis and therapy options of clear cell renal cell carcinoma. Scientific Reports. 2020;10(1):1–15. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 74.Arisan ED, Dart A, Grant GH, Arisan S, Cuhadaroglu S, Lange S, et al. The prediction of miRNAs in SARS-CoV-2 genomes: hsa-miR databases identify 7 key miRs linked to host responses and virus pathogenicity-related KEGG pathways significant for comorbidities. Viruses. 2020;12(6):614. doi: 10.3390/v12060614 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 75.Peng S, Wang J, Wei S, Li C, Zhou K, Hu J, et al. Endogenous cellular microRNAs mediate antiviral defense against influenza A virus. Molecular Therapy-Nucleic Acids. 2018;10:361–75. doi: 10.1016/j.omtn.2017.12.016 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 76.Sang H-y, Jin Y-l, Zhang W-q, Chen L-b. Downregulation of microRNA-637 increases risk of hypoxia-induced pulmonary hypertension by modulating expression of cyclin dependent kinase 6 (CDK6) in pulmonary smooth muscle cells. Medical science monitor: international medical journal of experimental and clinical research. 2016;22:4066. doi: 10.12659/msm.897254 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 77.Yan Q, Ma X, Shen C, Cao X, Feng N, Qin D, et al. Inhibition of Kaposi’s sarcoma-associated herpesvirus lytic replication by HIV-1 Nef and cellular microRNA hsa-miR-1258. Journal of virology. 2014;88(9):4987–5000. doi: 10.1128/JVI.00025-14 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 78.Song J, Hu Y, Li H, Huang X, Zheng H, Hu Y, et al. miR-1303 regulates BBB permeability and promotes CNS lesions following CA16 infections by directly targeting MMP9. Emerging microbes & infections. 2018;7(1):1–15. doi: 10.1038/s41426-018-0157-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 79.Sung T-L, Rice AP. miR-198 inhibits HIV-1 gene expression and replication in monocytes and its mechanism of action appears to involve repression of cyclin T1. PLoS pathogens. 2009;5(1):e1000263. doi: 10.1371/journal.ppat.1000263 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 80.Bagasra O, Shamabadi NS, Pandey P, Desoky A, McLean E. Differential expression of miRNAs in a human developing neuronal cell line chronically infected with Zika virus. Libyan Journal of Medicine. 2021;16(1):1909902. doi: 10.1080/19932820.2021.1909902 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 81.Orumaa K, Dunne MR. The role of unconventional T cells in COVID-19. Irish Journal of Medical Science (1971-). 2021:1–10. doi: 10.1007/s11845-021-02653-9 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 82.Hasan MZ, Islam S, Matsumoto K, Kawai T. SARS-CoV-2 infection initiates interleukin-17-enriched transcriptional response in different cells from multiple organs. Scientific reports. 2021;11(1):1–11. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 83.Das D, Podder S. Unraveling the molecular crosstalk between Atherosclerosis and COVID-19 comorbidity. Computers in biology and medicine. 2021;134:104459. doi: 10.1016/j.compbiomed.2021.104459 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 84.Gupta RK, Nwachuku EL, Zusman BE, Jha RM, Puccio AM. Drug repurposing for COVID-19 based on an integrative meta-analysis of SARS-CoV-2 induced gene signature in human airway epithelium. Plos one. 2021;16(9):e0257784. doi: 10.1371/journal.pone.0257784 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 85.Ai J, Hong W, Wu M, Wei X. Pulmonary vascular system: A vulnerable target for COVID‐19. MedComm. 2021. doi: 10.1002/mco2.94 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 86.Donlan AN, Sutherland TE, Marie C, Preissner S, Bradley BT, Carpenter RM, et al. IL-13 is a driver of COVID-19 severity. medRxiv. 2021:2020.06. 18. doi: 10.1097/WNR.0b013e328337750f [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 87.Rincon‐Arevalo H, Aue A, Ritter J, Szelinski F, Khadzhynov D, Zickler D, et al. Altered increase in STAT1 expression and phosphorylation in severe COVID‐19. European Journal of Immunology. 2021. doi: 10.1002/eji.202149575 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 88.Giovannoni F, Li Z, Remes-Lenicov F, Dávola ME, Elizalde M, Paletta A, et al. AHR signaling is induced by infection with coronaviruses. Nature communications. 2021;12(1):1–12. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 89.Gisby J, Clarke CL, Medjeral-Thomas N, Malik TH, Papadaki A, Mortimer PM, et al. Longitudinal proteomic profiling of dialysis patients with COVID-19 reveals markers of severity and predictors of death. Elife. 2021;10:e64827. doi: 10.7554/eLife.64827 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 90.Balnis J, Madrid A, Hogan KJ, Drake LA, Chieng HC, Tiwari A, et al. Blood DNA methylation and COVID-19 outcomes. Clinical epigenetics. 2021;13(1):1–16. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 91.Lu S, Zhu N, Guo W, Wang X, Li K, Yan J, et al. RNA-Seq revealed a circular RNA-microRNA-mRNA regulatory network in Hantaan virus infection. Frontiers in cellular and infection microbiology. 2020;10:97. doi: 10.3389/fcimb.2020.00097 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 92.Hu Y, Xu Y, Deng X, Wang R, Li R, You L, et al. Comprehensive analysis of the circRNA expression profile and circRNA-miRNA-mRNA network in the pathogenesis of EV-A71 infection. Virus Research. 2021;303:198502. doi: 10.1016/j.virusres.2021.198502 [DOI] [PubMed] [Google Scholar]
  • 93.Ai J, Li Y, Zhou X, Zhang W. COVID-19: treating and managing severe cases. Cell Research. 2020;30(5):370–1. doi: 10.1038/s41422-020-0329-2 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 94.Organization WH. Therapeutics and COVID-19: living guideline, 14 January 2022. World Health Organization, 2022. [PubMed] [Google Scholar]

Decision Letter 0

Kanhaiya Singh

10 Jan 2023

PONE-D-22-34657Mapping CircRNA–miRNA–mRNA Regulatory Axis Identifies hsa_circ_0080942 and hsa_circ_0080135 as a potential theranostic agents for SARS-CoV-2 infectionPLOS ONE

Dear Dr. Awan,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Feb 24 2023 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Kanhaiya Singh, Ph.D

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at 

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and 

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. We noted in your submission details that a portion of your manuscript may have been presented or published elsewhere. [All the datasets analyzed during the current study are accessible from the literature as well as from the GEO database (https://www.ncbi.nlm.nih.gov/gds/) with accession details (GSE166552, GSE19137, PRJCA002617, (McDonald, Enguita et al. 2021), (Arora, Singh et al. 2020), (Farr, Rootes et al. 2021), (Li, Hu et al. 2020), (Chow and Salmena 2020), (Demirci and Demirci 2021), (Chi, Ge et al. 2020), (Lin, Luo et al. 2020), (Chen, Wu et al. 2020), (Chen, Liu et al. 2020), (Blanco-Melo, Nilsson-Payant et al. 2020), (Li, Hu et al. 2020), (Del Valle, Kim-Schulze et al. 2020), (Qin, Zhou et al. 2020), (Yang, Shen et al. 2020), (Dhar, Vishnupriyan et al. 2021), and (Huang, Wang et al. 2020) datasets).] Please clarify whether this [conference proceeding or publication] was peer-reviewed and formally published. If this work was previously peer-reviewed and published, in the cover letter please provide the reason that this work does not constitute dual publication and should be included in the current manuscript.

3. Please upload a new copy of Figure 7 as the detail is not clear. Please follow the link for more information: https://blogs.plos.org/plos/2019/06/looking-good-tips-for-creating-your-plos-figures-graphics/" https://blogs.plos.org/plos/2019/06/looking-good-tips-for-creating-your-plos-figures-graphics/

4.  Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

Additional Editor Comments:

Although the reviewers have found this study of interest they have raised some concerns about method adopted.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: Manuscript Number: PONE-D-22-34657

Title: “Mapping CircRNA–miRNA–mRNA Regulatory Axis Identifies hsa_circ_0080942 and hsa_circ_0080135 as a potential theranostic agents for SARS-CoV-2 infection”

This is an interesting small study and the authors have collected a unique dataset using cutting edge methodology. The paper is well written and structured.

The following minor issues should be addressed:

1) In introduction section first paragraph author may update number of total people have been infected and death globally with virus SARS-CoV-2 with updated references.

Reviewer #2: The manuscript entitled Mapping CircRNA–miRNA–mRNA Regulatory Axis Identifies hsa_circ_0080942 and hsa_circ_0080135 as a potential theranostic agents for SARS-CoV-2 infection can be accepted for publication after few improvements

The author have selected the common circRNAs from circRNA datasets, mRNA datasets, and miRNA datasets. How the author found cicRNAs from mRNAs and miRNAs datasets? The authors are suggested to clearly describe the results in detail rather than superficial writing.

Why the author has used differentially expressed mRNA obtained from the mRNA datasets for the GO and KEGG pathway analysis? Why author not preferred the common mRNA which are target of circRNA as well as predicted from mRNA datasets.

The quality of image needs to be improved as picture is blur and not clear

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: Yes: Santosh Kumar

Reviewer #2: No

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

Attachment

Submitted filename: Manuscript Number PONE D 22 34657.docx

PLoS One. 2023 Apr 13;18(4):e0283589. doi: 10.1371/journal.pone.0283589.r002

Author response to Decision Letter 0


23 Feb 2023

Response to reviewers

Dear Editor,

We wish to express our appreciation for your in-depth comments, suggestions and corrections, and we would like to convey our sincere thanks for allowing us to improve our manuscript entitled “Mapping CircRNA–miRNA–mRNA Regulatory Axis Identifies hsa_circ_0080942 and hsa_circ_0080135 as a potential theranostic agents for SARS-CoV-2 infection”.

Thank you for your very careful review of our paper. A major revision of the paper has been carried out to take all of weaknesses and limitations identified by the respective reviewers into account. And in the process, we truly hope that the revised manuscript is clear enough to follow.

Below is an abridged summary of reviewer’s comments with a detailed response and description of the changes made to the article. Should you find the paper requires further clarification or revision, we most certainly stand ready to do so.

Looking forward to your positive response

Sincerely,

Dr. Faryal Mehwish Awan

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

Comment # 1

Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming.

Response

We have formatted our manuscript according to PLOS ONE’s style. The format has been updated in the revised version of the manuscript as per journal requirements.

Comment # 2

We noted in your submission details that a portion of your manuscript may have been presented or published elsewhere. [All the datasets analyzed during the current study are accessible from the literature as well as from the GEO database (https://www.ncbi.nlm.nih.gov/gds/) with accession details (GSE166552, GSE19137, PRJCA002617, (McDonald, Enguita et al. 2021), (Arora, Singh et al. 2020), (Farr, Rootes et al. 2021), (Li, Hu et al. 2020), (Chow and Salmena 2020), (Demirci and Demirci 2021), (Chi, Ge et al. 2020), (Lin, Luo et al. 2020), (Chen, Wu et al. 2020), (Chen, Liu et al. 2020), (Blanco-Melo, Nilsson-Payant et al. 2020), (Li, Hu et al. 2020), (Del Valle, Kim-Schulze et al. 2020), (Qin, Zhou et al. 2020), (Yang, Shen et al. 2020), (Dhar, Vishnupriyan et al. 2021), and (Huang, Wang et al. 2020) datasets).] Please clarify whether this [conference proceeding or publication] was peer-reviewed and formally published. If this work was previously peer-reviewed and published, in the cover letter please provide the reason that this work does not constitute dual publication and should be included in the current manuscript.

Response

Yes, we agree with the observation that all the datasets analyzed are already available publically. However, current study does not constitute as dual publication because this study only used the available datasets for novel integrative analysis in order to identify most promising and potential drug targets and to develop appropriate therapeutic strategies. It is important to note that the Gene Expression Omnibus (GEO) repository archives and freely distributes microarray, next-generation sequencing and other forms of high-throughput functional genomics data. Such datasets hold great value for knowledge discovery, particularly when integrated and can potentially bring novel insights into essential questions. The present study has aimed at prioritizing the potential circRNA candidates for a prospective theranostic evaluation via exploring the existing publically available datasets in COVID-19 setting. Public databases have a lot of high throughput data, which greatly helps in revealing the possible disease pathogenesis and identifying potential targets for drug design. Experimental validation of all the discovered associations, let alone all the possible interactions between them, is time-consuming and expensive. In conventional approaches, large experimental screenings are currently used to identify potential leading compounds, but they require significant time and resources. However, one of the lessons learned during the current pandemic is that innovative approaches are required to speed up drug development while increasing its success rate. Since gene expression data are high-dimensional data, an important research aim in the analysis of transcription profiles is the discovery of small subset of biomarkers containing the most discriminant information. Therefore, current study computationally prioritized the data available in the databases for potential SARS-CoV-2 inhibitors by using an integrated approach.

A number of recently published research studies have utilized publically available datasets for the prioritization of most promising candidates. Some of these studies are (Dat, et al., 2022; Pandya, et al., 2020; Shams, et al., 2020; Venugopal, et al., 2022; Wu, et al., 2021; Zhang, et al., 2021)

We have added this information in the cover letter to clarify this comment.

Comment: 3

Please upload a new copy of Figure 7 as the detail is not clear. Please follow the link for more information: https://blogs.plos.org/plos/2019/06/looking-good-tips-for-creating-your-plos-figures-graphics/" https://blogs.plos.org/plos/2019/06/looking-good-tips-for-creating-your-plos-figures-graphics/

Response

We agree with your assessment. We have now followed figure graphics requirements for all the figures and have also uploaded a new copy of Figure 7 as “Fig7.tif”.

Fig 7: Pathway analysis of COVID-19 pathogenesis (KEGG pathway ID: map05171). Highlighted genes are targets of miRNAs and indirect targets of two prioritized circRNAs

Comment: 4

Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

Response

We have rechecked the whole manuscript for any errors in the references. Corrections have been made and highlighted.

Reviewer #1

Comments and Suggestions for Authors

This is an interesting small study and the authors have collected a unique dataset using cutting edge methodology. The paper is well written and structured.

Response

We appreciate the positive feedback from the reviewer and would like to thank the respected reviewer for the encouraging assessment and the comments that helped us to improve the manuscript.

Comment: 1

The following minor issues should be addressed:

In introduction section first paragraph author may update number of total people have been infected and death globally with virus SARS-CoV-2 with updated references.

Response

We agree with your assessment. As per your suggestion, we have updated total number as per World Health Organization report and revised the statement as follows.

Currently, >750 million people have been infected globally while >6.8 million people have lost their lives due to COVID-19 (World Health Organization, February 22, 2023).

We have updated this information in the revised version of the manuscript.

Reviewer #2

Comments and Suggestions for Authors

The manuscript entitled Mapping CircRNA–miRNA–mRNA Regulatory Axis Identifies hsa_circ_0080942 and hsa_circ_0080135 as a potential theranostic agents for SARS-CoV-2 infection can be accepted for publication after few improvements

Response

We appreciate the positive feedback from the reviewer and would like to thank the respected reviewer for the encouraging assessment and the comments that helped us to improve the manuscript.

Comment: 1

The author have selected the common circRNAs from circRNA datasets, mRNA datasets, and miRNA datasets. How the author found cicRNAs from mRNAs and miRNAs datasets? The authors are suggested to clearly describe the results in detail rather than superficial writing.

Response

The target circRNAs of differentially expressed miRNAs were predicted using different comprehensive databases including CircBank, CircInteractome and RNAInter v4.0 web tools (Table 2). CircBank (http://www.circbank.cn/) is a comprehensive, publicly available, functionally annotated human circRNAs database containing information of about 140,000 circRNAs from many different sources (Liu, et al., 2019). The Users can access information regarding conservation status, miRNA targets as well as protein coding potential of query circRNAs (Liu, et al., 2019). CircInteractome (https://circinteractome.nia.nih.gov/) is a readily accessible web tool for mapping miRNAs and protein-binding sites on junctions as well as junction-flanking sequences of human circRNAs (Dudekula, et al., 2016). RNA Interactome Database, RNAInter v4.0 (http://www.rnainter.org/) is a comprehensive RNA-associated interactome platform containing information of more than 41 million interactions of cellular RNAs in 154 species with evidence from both computational and experimental sources (Kang, et al., 2021). Selection criteria, threshold and prediction scores for each database were selected on the basis of their previously reported relationship with low false discovery rate and high accuracy in experimental validation studies via PCR and Luciferase assays.

For the prediction of potential circRNAs associated with differentially expressed mRNAs, first we predicted miRNAs associated with these mRNA and then circRNAs associated with predicted miRNAs. We used databases including miRDB, miRWalk 2.0, miRTarBase, and TargetScan 7.0 for the prediction of miRNAs associated with respective mRNAs. miRDB (http://mirdb.org/), is an integrative, freely accessible, open platform for the prediction of miRNA targets. miRNA-target interactions with scores ≥80.0 were considered relevant, statistically significant and with higher confidence in the interactions whereas miRNA-target interactions with scores ≤80.0 were considered not relevant. By utilizing high-throughput experimental data, miRDB predicts miRNA targets in five species along with integrative analysis of gene ontology (GO) data (Wang, 2008). miRWalk 2.0 (http://mirwalk.umm.uni-heidelberg.de/) provides information of more than 949 million computationally predicted as well as experimentally validated miRNA-mRNA interactions. In order to ensure reliability and accuracy of forecast results, miRWalk 2.0 incorporates 12 algorithms for prediction including miRWalk, mirbridge, Targetscan, Microt4, PITA, Pictar2, RNAhybrid, RNA22, miRNAMap, miRanda, miRMap and miRDB (Dweep and Gretz, 2015). Cut-off value with a binding score of > 0.95 was considered as a screening threshold. miRTarBase (https://miRTarBase.cuhk.edu.cn/~miRTarBase/miRTarBase_2022/php/index.php) is a manually curated database containing information of more than 360,000 experimentally validated miRNA-mRNA interactions (Huang, et al., 2020). miRNA-mRNA interactions have been validated experimentally using microarray, CLIP-seq technology, reporter assays, high through-put sequencing and western blot experiments (Huang, et al., 2020). All the targets identified via miRTarBase were selected for further analysis. TargetScan v7.0 (http://www.targetscan.org/vert_80/), a flexible web based tool, predicts sequence based effective regulatory targets of miRNAs by incorporating 14 different features (Agarwal, et al., 2015). Conservation aggregate score of > 0.80 was considered as selection criteria as this score provides low false discovery rates. An overlap in at least two databases was used as filtering criteria for prioritizing and considering potential candidate targets. Previous comparative studies conducted on miRNA target prediction programs suggested that no program performed consistently superior to all others. Indeed, it has become a common practice for researchers to look at predictions produced by different miRNA-target prediction programs and focus on their intersection which might enhances the performance of analyses as well as improve prediction precision. The differences between algorithms are mostly seen in their respective weaknesses, i.e., the subset of false positives. For that reason, the fundamental motivation to focus selectively on the shared prediction by two algorithms is to eliminate false positives while preserving the vast majority of true positive RNAs. Therefore, conclusively, predictions are much more reliable when two or more prediction algorithms are combined, and the minimal loss of true positives are greatly outweighed by the removal of false positives. Comprehensive analysis of differentially expressed miRNA datasets revealed 38937 target circRNAs. On the other hand, comprehensive analysis of 5109 predicted miRNAs against differentially expressed mRNAs revealed 858423 circRNAs having binding sites for respective miRNAs.

Comment: 2

Why the author has used differentially expressed mRNA obtained from the mRNA datasets for the GO and KEGG pathway analysis? Why author not preferred the common mRNA which are target of circRNA as well as predicted from mRNA datasets.

Response

The most common complication associated with this COVID-19 is the cytokine storm which is responsible for mortality. Thus, targeting the cytokine storm with new medications is needed to hamper COVID-19 complications. The purpose of performing KEGG pathway analysis was to identify relationship between COVID-19 induced cytokine storm related genes and prioritized circRNAs including hsa_circ_0080942 and hsa_circ_0080135 from final circRNAs-miRNAs-mRNAs axis. The hsa_circ_0080942 network included 47 miRNAs and 15 cytokine storm related genes forming 88 pairs of circRNA-miRNA-mRNA axis. The hsa_circ_0080135 network included 39 miRNAs and 15 cytokine storm related genes forming 77 pairs of circRNA-miRNA-mRNA axis. We proposed that via targeting two prioritized circRNAs, maximum number of cytokines dysregulated during SARS-CoV-2 infection can be targeted as represented from the Figure 7.

Fig 7: Pathway analysis of COVID-19 pathogenesis (KEGG pathway ID: map05171). Highlighted genes are targets of miRNAs and indirect targets of two prioritized circRNAs

Comment: 3

The quality of image needs to be improved as picture is blur and not clear

Response

We agree with your assessment. We have now uploaded a new copy of Figure 7 as “Fig7.tif”. In addition we have also updated “Table 4” in tabular text form previously uploaded as a figure due to complexity of data.

Fig 7: Pathway analysis of COVID-19 pathogenesis (KEGG pathway ID: map05171). Highlighted genes are targets of miRNAs and indirect targets of two prioritized circRNAs

Table 4: Datasets used for the analysis of SARS-CoV-2 related cytokines

Genes Study 1 Study 2 Study 3 Study 4 Study 5 Study 6 Study 7 Study 8 Study 9 Study 10 Study 11 Study 12

up-regulated down-regulated up-regulated down-regulated up-regulated down-regulated up-regulated down-regulated up-regulated down-regulated up-regulated down-regulated up-regulated down-regulated up-regulated down-regulated up-regulated down-regulated up-regulated down-regulated up-regulated down-regulated up-regulated down-regulated

IL-1β _ _ _ _ _ _ _ _ √ _ _ _ √ _ _ _ _ _ _ _ √ _ _ _

IL-2 √ _ _ _ _ _ _ _ _ _ _ _ √ _ _ _ _ _ _ _ _ _ √ _

IL-4 _ _ _ _ _ _ _ _ _ _ _ _ √ _ _ _ _ _ _ _ _ _ √ _

IL-6 _ _ √ _ √ _ _ _ √ _ √ _ √ _ √ _ √ _ √ _ √ _ √ _

IL-7 √ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ √ _ _ _ _ _

IL-8 _ _ _ _ _ _ _ _ √ _ √ _ _ _ √ _ _ _ √ _ _ _ _ _

IL-10 √ _ _ _ √ _ _ _ √ _ _ _ √ _ _ _ _ _ √ _ _ _ √ _

IL-12 _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _

IL-13 _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ √ _ _ _

IL-17 _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _

IL-18 _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ √ _ √ _ _ _

IL-23 _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _

IL-33 _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _

IL-37 _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _

IL-38 _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _

TNF-α √ _ _ _ √ _ _ _ √ _ √ _ √ _ √ _ _ _ _ _ _ _ √ _

IFN-γ _ _ _ _ √ _ _ _ _ _ _ _ √ _ _ _ _ _ _ _ _ _ √ _

CCL2 _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ √ _ _ _ _ _ _ _

CXCL6 _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _

CXCL8 _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ √ _ _ _ _ _ _ _

CXCL10 _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ √ _ _ _ _ _ _ _

IP-10 √ _ _ _ _ _ √ _ _ _ _ _ _ _ _ _ _ _ √ _ √ _ _ _

MIP-1A √ _ _ _ _ _ √ _ _ _ _ _ _ _ _ _ _ _ √ _ √ _ _ _

MIP1-B _ _ _ _ _ _ √ _ _ _ _ _ _ _ _ _ _ _ _ _ √ _ _ _

PDGF _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ √ _ _ _

MCP1 √ _ _ _ _ _ √ _ _ _ _ _ _ _ _ _ _ _ √ _ _ _ _ _

GM-CSF _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _

M-CSF _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ √ _ √ _ _ _

G-CSF √ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ √ _ √ _ _ _

FGF _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _

HGF _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ √ _ _ _

TGF-β _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _

(Huang, et al., 2020)

(Chen, et al., 2020)

(Chen, et al., 2020)

(Liu, et al., 2020)

(Qin, et al., 2020)

(Farr, et al., 2021)

(Dhar, et al., 2021)

(Del Valle, et al., 2020)

(Blanco-Melo, et al., 2020)

(Chi, et al., 2020)

(Yang, et al., 2020)

(Lin, et al., 2020)

We hope that our additions to the manuscript will satisfy the reviewers, and thank both reviewers for their precise and insightful comments, and for the careful attention that they have paid which allowed us to improve the manuscript. We look forward to hearing from you regarding our submission. We would be glad to respond to any further questions and comments that you may have.

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

Reviewer #1: Yes

Reviewer #2: Yes

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

3. Have the authors made all data underlying the findings in their manuscript fully available?

Reviewer #1: Yes

Reviewer #2: Yes

4. Is the manuscript presented in an intelligible fashion and written in standard English?

Reviewer #1: Yes

Reviewer #2: Yes

References

Agarwal, V., et al. (2015) Predicting effective microRNA target sites in mammalian mRNAs, elife, 4, e05005.

Blanco-Melo, D., et al. (2020) Imbalanced host response to SARS-CoV-2 drives development of COVID-19, Cell, 181, 1036-1045. e1039.

Chen, G., et al. (2020) Clinical and immunological features of severe and moderate coronavirus disease 2019, The Journal of clinical investigation, 130, 2620-2629.

Chen, L., et al. (2020) Analysis of clinical features of 29 patients with 2019 novel coronavirus pneumonia, Zhonghua jie he he hu xi za zhi= Zhonghua jiehe he huxi zazhi= Chinese journal of tuberculosis and respiratory diseases, 43, E005-E005.

Chi, Y., et al. (2020) Serum cytokine and chemokine profile in relation to the severity of coronavirus disease 2019 in China, The Journal of infectious diseases, 222, 746-754.

Dat, V.H.X., et al. (2022) Identification of potential microRNA groups for the diagnosis of hepatocellular carcinoma (HCC) using microarray datasets and bioinformatics tools, Heliyon, 8, e08987.

Del Valle, D.M., et al. (2020) An inflammatory cytokine signature predicts COVID-19 severity and survival, Nature medicine, 26, 1636-1643.

Dhar, S.K., et al. (2021) IL-6 and IL-10 as predictors of disease severity in COVID-19 patients: results from meta-analysis and regression, Heliyon, 7, e06155.

Dudekula, D.B., et al. (2016) CircInteractome: a web tool for exploring circular RNAs and their interacting proteins and microRNAs, RNA biology, 13, 34-42.

Dweep, H. and Gretz, N. (2015) miRWalk2. 0: a comprehensive atlas of microRNA-target interactions, Nature methods, 12, 697-697.

Farr, R., et al. (2021) Altered microRNA expression in COVID-19 patients enables identification of SARS-CoV-2 infection.

Huang, C., et al. (2020) Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China, The lancet, 395, 497-506.

Huang, H.-Y., et al. (2020) miRTarBase 2020: updates to the experimentally validated microRNA–target interaction database, Nucleic acids research, 48, D148-D154.

Kang, J., et al. (2021) RNAInter v4. 0: RNA interactome repository with redefined confidence scoring system and improved accessibility, Nucleic acids research.

Lin, L., et al. (2020) Long-term infection of SARS-CoV-2 changed the body's immune status, Clinical Immunology, 218, 108524.

Liu, J., et al. (2020) Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients, EBioMedicine, 55, 102763.

Liu, M., et al. (2019) Circbank: a comprehensive database for circRNA with standard nomenclature, RNA biology, 16, 899-905.

Pandya, P.H., et al. (2020) Systems biology approach identifies prognostic signatures of poor overall survival and guides the prioritization of novel bet-chk1 combination therapy for osteosarcoma, Cancers, 12, 2426.

Qin, C., et al. (2020) Dysregulation of immune response in patients with coronavirus 2019 (COVID-19) in Wuhan, China, Clinical infectious diseases, 71, 762-768.

Shams, R., et al. (2020) Identification of potential microRNA panels for pancreatic cancer diagnosis using microarray datasets and bioinformatics methods, Scientific Reports, 10, 7559.

Venugopal, P., et al. (2022) Prioritization of microRNA biomarkers for a prospective evaluation in a cohort of myocardial infarction patients based on their mechanistic role using public datasets, Frontiers in Cardiovascular Medicine, 9.

Wang, X. (2008) miRDB: a microRNA target prediction and functional annotation database with a wiki interface, Rna, 14, 1012-1017.

Wu, A.T., et al. (2021) Multiomics identification of potential targets for Alzheimer disease and antrocin as a therapeutic candidate, Pharmaceutics, 13, 1555.

Yang, Y., et al. (2020) Plasma IP-10 and MCP-3 levels are highly associated with disease severity and predict the progression of COVID-19, Journal of Allergy and Clinical Immunology, 146, 119-127. e114.

Zhang, P., et al. (2021) Bioinformatics analysis of candidate genes and pathways related to hepatocellular carcinoma in China: a study based on public databases, Pathology and Oncology Research, 13.

Attachment

Submitted filename: Response to reviewers.docx

Decision Letter 1

Kanhaiya Singh

13 Mar 2023

Mapping CircRNA–miRNA–mRNA Regulatory Axis Identifies hsa_circ_0080942 and hsa_circ_0080135 as a potential theranostic agents for SARS-CoV-2 infection

PONE-D-22-34657R1

Dear Dr. Awan,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Kanhaiya Singh, Ph.D

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #2: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #2: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #2: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #2: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #2: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #2: Following the suggestions, the author has addressed the issues and modified the manuscript accordingly and can be considered for the publication

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #2: No

**********

Acceptance letter

Kanhaiya Singh

4 Apr 2023

PONE-D-22-34657R1

Mapping CircRNA–miRNA–mRNA Regulatory Axis Identifies hsa_circ_0080942 and hsa_circ_0080135 as a potential theranostic agents for SARS-CoV-2 infection

Dear Dr. Awan:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Kanhaiya Singh

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    Attachment

    Submitted filename: Manuscript Number PONE D 22 34657.docx

    Attachment

    Submitted filename: Response to reviewers.docx

    Data Availability Statement

    Availability of Data and Materials The authors declare that the data supporting the findings of this study are addressed within the article and confirm that all the datasets analyzed during the current study are accessible from the literature as well as from the GEO database (https://www.ncbi.nlm.nih.gov/gds/) with accession details (GSE166552, GSE19137, PRJCA002617, (McDonald, Enguita et al. 2021), (Arora, Singh et al. 2020), (Farr, Rootes et al. 2021), (Li, Hu et al. 2020), (Chow and Salmena 2020), (Demirci and Demirci 2021), (Chi, Ge et al. 2020), (Lin, Luo et al. 2020), (Chen, Wu et al. 2020), (Chen, Liu et al. 2020), (Blanco-Melo, Nilsson-Payant et al. 2020), (Li, Hu et al. 2020), (Del Valle, Kim-Schulze et al. 2020), (Qin, Zhou et al. 2020), (Yang, Shen et al. 2020), (Dhar, Vishnupriyan et al. 2021), and (Huang, Wang et al. 2020) datasets).


    Articles from PLOS ONE are provided here courtesy of PLOS

    RESOURCES